Category: General News
Search News
Immunotherapy shows promise for patients with metastatic triple-negative breast cancer
17th October 2018
Immunotherapy has been shown to confer an encouraging survival benefit in patients with metastatic triple-negative breast cancer (mTNBC).
Read more
Accelerator Award to improve early detection and intervention of blood cancers
9th October 2018
BCI researchers are lead members of an international team to be funded by an Accelerator Award, which will bring together scientists from the UK, Spain and Italy in a bid to improve early detection and intervention of blood cancers.
Read more
Blood Cancer Awareness Month 2018
28th September 2018
Blood Cancer Awareness Month takes place every September to raise awareness of the challenges faced by those living with blood cancer. In the UK, blood cancer is the fifth most common cancer, with 240,000 people living with the disease and 38,000 people being diagnosed with a type of blood cancer each year.
Read more
World Cancer Research Day 2018
24th September 2018
The 24th September is World Cancer Research Day- a day dedicated to raising awareness of the importance of cancer research. Thanks to a united effort by researchers from around the world, cancer survival rates have doubled in the last 40 years, and 50% of those diagnosed with cancer now survive.
Read more
CRUK Barts Centre key partner in new £14m CRUK City of London Centre
17th September 2018
We are delighted to announce that researchers from the Barts Cancer Research UK Barts Centre will play a leading role in the new Cancer Biotherapeutics Hub launched by CRUK – The ‘CRUK City of London Centre’. The new centre will bring together world-leading cancer researchers from across London – CRUK Barts Centre, UCL, KCL and the Francis Crick Institute.
Read more
Study links widely-used drug azathioprine to skin cancers
14th September 2018
A drug used to treat inflammatory bowel disease and arthritis, and prevent organ rejection in transplant patients, has been identified as an important contributor to skin cancer development in a study by researchers from Queen Mary University of London, including our Barts Cancer Research UK Centre (BCC) Bioinformatics team, the University of Dundee and the Wellcome Sanger Institute.
Read more